New clinical studies that are now accepting enrollment:
Protocol FID33: Safety and Immunogenicity of Revaccination with Influenza Vaccine in Healthy Adult Subjects aged 18 to 64 Years who were Previously Vaccinated with Fluzone ID or Fluzone IM. For more information, please contact Vicki Cannon @ 817-735-2363.
An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs. For more information, please contact Cynthia Jimenez-Williams @ 817-735-0317.
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PARALLEL?GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE COMPARED WITH INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB. For more information, please contact Cynthia Jimenez-Williams at 817-735-0317.
Are you a woman age 45 to 65 who is currently experiencing hot flashes and no longer having periods? Or Are you a woman age 45 to 65 who has never experienced hot flashes and are no longer having periods? The purpose of this research study is to determine whether hot flashes have an effect on blood pressure and heart health in African American, Caucasian, and Hispanic women. Please contact Kim at 817-735-2694 or kbrown@hsc.unt.edu for more information about this study.
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus For more information, please contact Della Weis @ 817-735-0304. research/clinicaltrials/documents/TOC110978%20Flyer%20for%20Daily%20News.pdf
A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS). For more information, please contact Della Weis @ 817-735-0304.
A Phase 4, Multicenter, Open-Label, Observational StudyAssessing the Impact of Exposure to THROMBIN-JMI ® (Thrombin, Topical U.S.P. [Bovine Origin]) on Coagulation Parameters. For more information, please contact Della Weis @ 817-735-0304.
A Phase III-B Multi-center Study with a 12 Week Double-blind, Placebo-controlled, Randomized Period, Followed by an Open-label Extension Phase to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered to Patients with Active Rheumatoid Arthritis. For more information, please contact Sandra Powell at 817-735-0591.
A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered with Routine Infant Vaccinations to Healthy Infants. For more information, please contact Vicki Cannon @ 817-735-2363.
A Phase 4, Multicenter, Open-label, Assessor-blinded, Switch Study of the Efficacy and Safety of Infliximab (REMICADE®) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL®) or Adalimumab (HUMIRA®) For more information, please contact Sandra Powell @ 817-737-0591.
Proteus EMITTER 2.0 Event Marker Ingested To Trigger Event Recorder 2.0 A Non-Significant Risk Feasibility Study of the RaisinTM Ingestible Event Marker System. For more information, please contact Della Weis @ 817-737-0304.
A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation. For more intormation, please contact Della Weis @ 817-737-0304.
Incidence of Hypocalcemia Post Reclast Treatment in Patients with Paget's Disease sponsored by Novartis. For more information, please contact Sandra Powell @ 817-735-0591.
A phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel Group, Efficacy and Safety trial of Bapineuzumab(AAB001,ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein Eε4 carriers. Please contact Barbara Harty @ 817-735-2193.
A phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel Group, Efficacy and Safety trial of Bapineuzumab(AAB001,ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein Eε4 non carriers. Please contact Barbara Harty @ 817-735-2193.
A 48 week, Multicenter, Randomized, Double blind, Parallel Group Evaluation of the Comparative Efficacy, Safety And Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer's Disease Showing Cognitive Decline during the initial Open-Label treatment phase. Please contact Barbara Harty @ 817-735-2193.
Meningitis and Meningococcal Disease in Infants. For more information about having your infant participate in a research study of an investigational infant vaccine for meningococcal disease, please contact Vicki Cannon 817-735-2363.
Strategic Timing of AntiRetroviral Treatment (START) A Multicenter Study of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). For more information, please contact Isabel Vecino at 817-321-4812
INSIGHT PROTOCOL 001:Strategic Timing of AntiRetroviral Treatment (START) A Multicenter Study of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). For more information, please contact Isabel Vecino at 817-321-4817.
This page last updated Oct 23, 2009
